‘Rare Disease Moonshot’ – Scaling-up public-private partnerships to accelerate research into world’s rarest diseases AMSTERDAM, Netherlands, December 8, 2022 — A new initiative to boost research and development into rare and paediatric diseases
December 16, 2022 eCOA Consortium and PRO Consortium Announce Publication of Two Open Access Articles C-Path’s eCOA Consortium and PRO Consortium are pleased to announce the publication of two open access articles in the Jour
December 16, 2022 Qualitative Interview Findings: Comparability of a Provisioned Device Versus Bring Your Own Device…
December 16, 2022 Quantitative Study Findings: Comparability of a Provisioned Device Versus Bring Your Own Device…
November 16, 2022 Empowering drug development: Leveraging insights from imaging technologies to enable the advancement of digital heath technologies
December 20, 2022 C-Path’s Transplant Therapeutics Consortium Receives EMA Qualification Opinion for iBox Scoring System The iBox Scoring System is available for use in kidney transplant clinical trials as a novel secondary endpoint prognostic for all
C-Path Receives Letter of Support from EMA for Parkinson’s Disease Clinical Trial Simulation Platform TUCSON, Ariz., Dec. 20, 2022 — Critical Path Institute (C-Path) today announced that the European Medicines Agency (EMA) has iss
Using Real World Data from CURE ID to Identify Drug Repurposing Opportunities in Mycology: Impact of Climate Change
September 21, 2022 Role of tigecycline in the treatment of urinary tract infections: a systematic review of published case reports
